The global, regional, and national burden of benign prostatic hyperplasia in 204 countries and territories from 2000 to 2019: a systematic analysis for the Global Burden of Disease Study 2019

Awedew, Atalel Fentahun; Han, Hannah; Abbasi, Behzad; Abbasi‐Kangevari, Mohsen; Ahmed, Muktar Beshir; Almidani, Omar; Amini, Erfan; Arabloo, Jalal; Mamo, Ayele; Athari, Seyyed Shamsadin; Atlaw, Daniel; Banach, Maciej; Barrow, Amadou; Bhagavathula, Akshaya Srikanth; Bhojaraja, Vijayalakshmi S; Bikbov, Boris; Bodicha, Belay Boda Abule; Butt, Nadeem Shafique; Santos, Florentino Luciano Caetano dos; Dadras, Omid; Dai, Xiaochen; Doan, Linh Phuong; Eftekharzadeh, Sahar; Fatehizadeh, Ali; Garg, Tushar; Gebremeskel, Teferi Gebru; Getachew, Motuma Erena; Ghamari, Seyyed‐Hadi; Gilani, Syed Amir; Golechha, Mahaveer; Gupta, Veer Bala; Gupta, Vivek Kumar; Hay, Simon I; Hosseini, Mohammad-Salar; Hosseinzadeh, Mehdi; Humayun, Ayesha; Ilić, Irena; Ilic, Milena D; Ismail, Nahlah Elkudssiah; Jakovljević, Mihajlo; Jayaram, Shubha; Jazayeri, Seyed Behzad; Jema, Alelign Tasew; Kabir, Ali; Karaye, Ibraheem M.; Khader, Yousef; Khan, Ejaz Ahmad; Landires, Iván; Lee, Sang-woong; Lee, Shaun Wen Huey; Lim, Stephen S; Lobo, Stany W.; Majeed, Azeem; Malekpour, Mohammad‐Reza; Malih, Narges; Malik, Ahmad Azam; Nasab, Entezar Mehrabi; Meštrović, Tomislav; Michałek, Irmina Maria; Mihrtie, Gedefaye Nibret; Mirza‐Aghazadeh‐Attari, Mohammad; Misganaw, Awoke; Mokdad, Ali H.; Molokhia, Mariam; Murray, Christopher J L; Swamy, Sreenivas Narasimha; Nguyen, Son Hoang; Nowroozi, Ali; Núñez-Samudio, Virginia; Owolabi, Mayowa; Pawar, Shrikant; Perico, Norberto; Rawaf, David Laith; Rawaf, Salman; Rawassizadeh, Reza; Remuzzi, Giuseppe; Sahebkar, Amirhossein; Sampath, Chethan; Shetty, Jeevan K.; Sibhat, Migbar Mekonnen; Singh, Jasvinder A; Tan, Ker‐Kan; Temesgen, Gebremaryam; Tolani, Musliu Adetola; Tovani‐Palone, Marcos Roberto; Tahbaz, Sahel Valadan; Valizadeh, Rohollah; Vo, Bay; Vu, Linh Gia; Yang, Lin; Yazdanpanah, Fereshteh; Yiğit, Arzu; Yiğit, Vahit; Yunusa, Ismaeel; Zahir, Mazyar; Vos, Theo; Dirac, M Ashworth

doi:10.1016/s2666-7568(22)00213-6

Cited by 57 publications

(30 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Longitudinal studies report an average annual growth rate of 2.0%-2.5% in older men 97,98 . This enlargement of the prostate gland can cause partial or complete obstruction of the urethra, leading to chronic lower urinary tract symptoms, but also more acute conditions like urinary tract infections, urinary retention, and renal failure 99 . Change in prostate volume has been used as an outcome in clinical trials assessing interventions targeting benign prostate hyperplasia 100 .…”

Section: Hyperplasia Of Prostatic Tissue (Benign Prostatic Hyperplasia)mentioning

confidence: 99%

In vivo medical imaging for assessing geroprotective interventions in humans

Svensson,

Schain,

Sigray

2024

Preprint

View full text Add to dashboard Cite

There is a growing interest in developing drugs with a general geroprotective effect, aimed at slowing down aging processes in humans. Several candidate compounds have already demonstrated increased lifespan and reduced incidence of age-related disease in short-lived model organisms. The extended lifespan of humans makes it challenging to translate these findings, especially if mortality or onset of age-related morbidity are to be used as trial endpoints. To address this, we propose using a battery of medical imaging protocols that allows for in vivo assessments of multiple age-related pathological processes known to precede onset of age-related disease. These protocols, based on magnetic resonance imaging, positron emission-, computer-, and optical coherence-tomography, are already in use in drug development and are available at most modern hospitals. Here, we outline how an informed use of these techniques allows for detecting changes in the accumulation of age-related pathologies in a diverse set of physiological systems, such as cardiovascular, kidney and metabolic function, periodontal inflammation, retinal or neuro-degeneration, and bone or muscle density. With this in vivo imaging battery, it is possible to screen for efficacy of candidate geroprotective compounds in early phase clinical trials, within reasonable trial durations.

show abstract

Section: Hyperplasia Of Prostatic Tissue (Benign Prostatic Hyperplasia)mentioning

confidence: 99%

In vivo medical imaging for assessing geroprotective interventions in humans

Svensson,

Schain,

Sigray

2024

Preprint

View full text Add to dashboard Cite

show abstract

“…BPH is histologically diagnosed based on the proliferation of smooth muscle and epithelial cells within the prostatic transition zone . BPH contributes to escalated health care costs and diminishes quality of life . α-blockers (terazosin, tamsulosin) and 5-α reductase inhibitors (finasteride and dutasteride) are classes of therapeutical modalities used in the management and treatment of BPH. , However, these medications exhibit certain adverse effects, including ejaculatory disorder, tremor, impotence, and the potential for progress to high-grade cancer. , Hence, there is a need to discover alternative agents that can have therapeutic effects and diminish unintended pharmacological effects.…”

Section: Introductionmentioning

confidence: 99%

New Pimarane Diterpenoids Isolated from EtOAc-Extract of Apiospora arundinis Culture Medium Show Antibenign Prostatic Hyperplasia Potential

Kwon,

Jin,

Kim

et al. 2024

ACS Omega

View full text Add to dashboard Cite

Three new pimarane diterpenoids, libertellenones U−W (1−3), together with libertellenone C (4) and myrocin A (5) were isolated from an EtOAc-extract of Apiospora arundinis culture medium. The chemical structures of the new compounds were elucidated using MS, NMR, and CD spectroscopic data. Benign prostatic hyperplasia (BPH), the abnormal and pathological proliferation of epithelial and stromal cells in prostatic tissues, is a common disease in middle-aged and elderly men. In this study, the anti-BPH effects of myrocin A (5) were evaluated using BPH-1 and WPMY-1 cells. Treatment with myrocin A (5) exerted antiproliferative effects in BPH-1 and dihydrotestosterone (DHT)-stimulated WPMY-1 cells. In BPH, treatment with myrocin A (5) significantly suppressed the mRNA levels of androgen receptor (AR) and its downstream targets nuclear receptor coactivator 1 (NCOA1), proliferating cell nuclear antigen (PCNA) and kallikrein-related peptidase 3 (KLK3). Additionally, DHT-stimulated WPMY-1 cells demonstrated an upregulated mRNA levels of AR, NCOA1, PCNA, and KLK3. However, treatment with myrocin A (5) resulted in suppression of the mRNA levels. Moreover, myrocin A (5) docked computationally into the binding site of the androgen receptor (−5.5 kcal/mol).

show abstract

“…Cardiovascular diseases and benign prostatic hyperplasia (BPH) are common conditions with shared risk factors among older men . The most prescribed class of medications for BPH consists of α-1 blockers (ABs), particularly selective antagonists of the α-1A adrenergic receptor (α1-A-AR) subtype .…”

Section: Introductionmentioning

confidence: 99%

Cardiovascular Outcomes of α-Blockers vs 5-α Reductase Inhibitors for Benign Prostatic Hyperplasia

Zhang,

Latour,

Olawore

et al. 2023

JAMA Netw Open

View full text Add to dashboard Cite

ImportanceThe most prescribed class of medications for benign prostatic hyperplasia (BPH) is α-blockers (ABs). However, the cardiovascular safety profile of these medications among patients with BPH is not well understood.ObjectiveTo compare the safety of ABs vs 5-α reductase inhibitors (5-ARIs) for risk of adverse cardiovascular outcomes.Design, Setting, and ParticipantsThis active comparator, new-user cohort study was conducted using insurance claims data from a 20% random sample of Medicare beneficiaries from 2007 to 2019 to evaluate the 1-year risk of adverse cardiovascular outcomes. Males aged 66 to 90 years were indexed into the cohort at new use of an AB or 5-ARI. Twelve months of continuous enrollment and at least 1 diagnosis code for BPH within 12 months prior to initiation were required. Data were analyzed from January 2007 through December 2019.ExposuresExposure was defined by a qualifying prescription fill for an AB or 5-ARI after at least 12 months without a prescription for these drug classes.Main Outcomes and MeasuresFollow-up began at a qualified refill for the study drug. Primary study outcomes were hospitalization for heart failure (HF), composite major adverse cardiovascular events (MACE; hospitalization for stroke, myocardial infarction, or death), composite MACE or hospitalization for HF, and death. Inverse probability of treatment and censoring-weighted 1-year risks, risk ratios (RRs), and risk differences (RDs) were estimated for each outcome.ResultsAmong 189 868 older adult males, there were 163 829 patients initiating ABs (mean [SD] age, 74.6 [6.2] years; 579 American Indian or Alaska Native [0.4%], 5890 Asian or Pacific Islander [3.6%], 9179 Black [5.6%], 10 610 Hispanic [6.5%], and 133 510 non-Hispanic White [81.5%]) and 26 039 patients initiating 5-ARIs (mean [SD] age, 75.3 [6.4] years; 76 American Indian or Alaska Native [0.3%], 827 Asian or Pacific Islander [3.2%], 1339 Black [5.1%], 1656 Hispanic [6.4%], and 21 605 non-Hispanic White [83.0%]). ABs compared with 5-ARIs were associated with an increased 1-year risk of MACE (8.95% [95% CI, 8.81%-9.09%] vs 8.32% [95% CI, 7.92%-8.72%]; RR = 1.08 [95% CI, 1.02-1.13]; RD per 1000 individuals = 6.26 [95% CI, 2.15-10.37]), composite MACE and HF (RR = 1.07; [95% CI, 1.03-1.12]; RD per 1000 individuals = 7.40 [95% CI, 2.88-11.93 ]), and death (RR = 1.07; [95% CI, 1.01-1.14]; RD per 1000 individuals = 3.85 [95% CI, 0.40-7.29]). There was no difference in risk for HF hospitalization alone.Conclusions and RelevanceThese results suggest that ABs may be associated with an increased risk of adverse cardiovascular outcomes compared with 5-ARIs. If replicated with more detailed confounder data, these results may have important public health implications given these medications’ widespread use.

show abstract

The global, regional, and national burden of benign prostatic hyperplasia in 204 countries and territories from 2000 to 2019: a systematic analysis for the Global Burden of Disease Study 2019

Cited by 57 publications

References 61 publications

In vivo medical imaging for assessing geroprotective interventions in humans

In vivo medical imaging for assessing geroprotective interventions in humans

New Pimarane Diterpenoids Isolated from EtOAc-Extract of Apiospora arundinis Culture Medium Show Antibenign Prostatic Hyperplasia Potential

Cardiovascular Outcomes of α-Blockers vs 5-α Reductase Inhibitors for Benign Prostatic Hyperplasia

Contact Info

Product

Resources

About